AVANIR Announces Corporate Update Conference Call

AVANIR Pharmaceuticals (AMEX:AVN) will host a conference
call on Wednesday, July 13th, at 4:30 p.m. Eastern to discuss the
global partnership with AstraZeneca and the further development of
AVANIR's Reverse Cholesterol Transport enhancing compounds for the
treatment of cardiovascular disease. Management will also review
recently announced corporate milestones, such as the submission of the
Company's New Drug Application for Neurodex(TM) in the treatment of
pseudobulbar affect, and the initiation of a Phase III clinical trial
for neuropathic pain.
   The conference call will be webcast live through AVANIR's
corporate website at http://www.avanir.com. The call will be hosted by
Charles Mathews, Chairman of the Board, and will include James Berg,
Vice President, Clinical and Regulatory Affairs; Marty Emanuele,
Ph.D., Vice President, Business Development; and Jagadish Sircar,
Ph.D., Vice President, Drug Development.
   It is recommended that you go to AVANIR's website at least 10
minutes in advance of the webcast to download any applicable software.
For those who cannot listen to the live broadcast, the online replay
will be available for 90 days, and a phone replay will be available
for 7 days by dialing 866-225-2976 (domestic) and 703-639-1127
(international) and entering the passcode 738943.
   AVANIR Pharmaceuticals is a pharmaceutical company focused on
developing and commercializing novel therapeutic products for the
treatment of chronic diseases. AVANIR's product candidates address
therapeutic markets that include central nervous system and
cardiovascular disorders, inflammation, and infectious disease. AVANIR
recently submitted to the FDA the last modules of its "rolling" new
drug application for Neurodex(TM) for the treatment of pseudobulbar
affect. Additionally, AVANIR has initiated a double-blind,
placebo-controlled, multi-center, Phase 3 clinical trial of
Neurodex(TM) in patients with diabetic neuropathic pain. Recently,
AVANIR partnered its preclinical research and development program for
inflammatory disease with Novartis and its preclinical cardiovascular
program with AstraZeneca. The Company's first commercialized product,
Abreva(R), is marketed in North America by GlaxoSmithKline Consumer
Healthcare and is the leading over-the-counter product for the
treatment of cold sores. Further information about AVANIR can be found
at www.avanir.com.
   Except for the historical information presented herein, matters
discussed in this press release contain forward-looking statements
that are subject to certain risks and uncertainties that could cause
actual results to differ materially from any future results,
performance or achievements expressed or implied by such statements.
Statements that are not historical facts, including statements that
are preceded by, followed by, or that include such words like
"estimate," "anticipate," "believe," "intend," "plan," or "expect" or
similar statements are forward-looking statements. Forward-looking
statements include, but are not limited to, risks associated with the
FDA's review of the Company's new drug application for Neurodex,
regulatory decisions by the FDA for the Company's drug candidates,
milestones, and royalties earned from licensees, and results of
clinical trials or product development efforts, as well as risks
described in the Company's most recent Annual Report on Form 10-K and
in subsequent quarterly reports on Form 10-Q and from time-to-time in
other publicly available information regarding the Company. Research
findings are not always supportable by evidence obtained from
subsequent clinical trials, and the Company can make no assurances
that clinical trials will yield positive results. Final review
decisions made by the FDA and other regulatory agencies concerning
clinical trial results are often unpredictable and outside the
influence and/or control of the company. The Company disclaims any
intent or obligation to update these forward-looking statements.